|
|
Article: Thiakis Series A Brings In [pounds sterling]10M For Obesity Program.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
In its first major financing round, Thiakis Ltd. added [pounds sterling]10 million (US$19 million) in a Series A to advance work on its obesity drug.
The investment syndicate was led by Novo A/S, of Bagsvaerd, Denmark, and Advent Venture Partners, of London, and also included existing shareholder London-based Imperial Innovations Ltd., the technology commercialization arm of Imperial College London. Thiakis was spun out of Imperial in June 2004, and was granted an exclusive license to intellectual property relating to gut hormones oxyntomodulin and PYY3-36 for obesity.
"We're still conducting our research through the college," ...